@elenaelena скажет, что нет данных что-то утверждать определенно. Есть вот у нас вот такой стейтмент.
Data on SARS-CoV-2 vaccines PLWH is limited but based on their safety profiles to date, and the nature of the vaccines, there is no reason for additional concern at present. PLWH, in particular those with more advanced immunodeficiency (defined as CD4 count <200/µL) can produce weaker responses to some vaccines but it is currently unknown whether this also applies to SARS-CoV-2 vaccines. PLWH were eventually included in the Pfizer and Moderna trials but no separate safety or efficacy analysis for this subgroup has yet been presented. For those with previous SARS-CoV-2 infection, vaccination is also recommended, as it is possible that post-infection immunity will wane. The ideal timing of vaccination has not yet been determined.
The question how far PLWH at higher risk should be prioritized for SARS-CoV-2 vaccination has not been answered unanimously throughout Europe. Some countries have recommended that all PLWH should be given priority for vaccination against COVID-19 together with other groups of people with comorbidities, once the most at-risk groups such as the elderly >80 years and frontline healthcare workers have received their vaccination. In Germany, all PLWH will be included in a third tier of priority patients along with individuals above 60 years of age, people with comorbidities such as chronic heart, renal and liver disease, and those working in key sectors like education. In the UK PLWH aged 16-65 years will be included in the sixth priority group for vaccination, after those aged 65 years and over, healthcare workers and people who are clinically extremely vulnerable. The Portuguese vaccination plan doesn’t refer to PLHIV in particular so the vaccination will occur according to the criteria of the national plan and the comorbidities present in PLHIV.